After withdrawal, GSK touts another Blenrep combo win as …
WEBMar 7, 2024 · GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. In patients with previously treated multiple myeloma, Blenrep beat Takeda’s...
GSK announces positive results from DREAMM-8 phase III trial for ...
WEBMar 7, 2024 · Blenrep (belantamab mafodotin) is a new antibody-drug conjugate for relapsed/refractory multiple myeloma. It extended progression-free survival and had a positive overall survival trend compared to standard of care in two phase III trials.
GSK details Blenrep combo data that could bring the multiple …
WEBFeb 5, 2024 · The combination of Blenrep with Takeda’s Velcade and the steroid dexamethasone (Vd) significantly cut the risk of progression or death by 59% compared with Johnson & Johnson’s Darzalex and Vd in...
FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for …
WEBGlaxoSmithKline announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory ...
Blenrep combination reduced the risk of disease progression or …
WEBJun 2, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory ...
GSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression …
WEBJun 3, 2024 · On Sunday, GSK plc (NYSE:GSK) released results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial evaluating Blenrep (belantamab mafodotin) in combination with pomalidomide plus...
DREAMM-7 phase III trial shows Blenrep combination nearly tripled ... - GSK
WEBFeb 5, 2024 · Blenrep (belantamab mafodotin) is a novel anti-BCMA antibody-drug conjugate for relapsed/refractory multiple myeloma. DREAMM-7 trial shows Blenrep combination nearly tripled PFS and reduced risk of …
DREAMM-8 Phase III Trial for Blenrep | Int'l Myeloma Foundation
WEBMar 7, 2024 · Blenrep, a novel antibody-drug conjugate, showed superior progression-free survival and a positive overall survival trend compared to bortezomib in a phase III trial for relapsed or refractory multiple myeloma. The trial was unblinded early based on the recommendation by an IDMC.
Phase III Blenrep Trial | Int'l Myeloma Foundation
WEBNov 27, 2023 · Blenrep is a novel antibody-drug conjugate that targets B-cell maturation antigen (BCMA) in multiple myeloma. The DREAMM-7 trial found that Blenrep plus bortezomib and dexamethasone improved progression-free survival and had a strong trend towards improved overall survival compared to daratumumab plus bortezomib and dexamethasone.
GSK backs up its Blenrep rehab bid with survival data
WEBSep 11, 2024 · GSK has reported data it hopes will allow a return to the US for Blenrep, the first BCMA-targeting drug to launch for multiple myeloma.
Skip to content